NEW YORK (Reuters) - A long-awaited experimental diabetes medicine from Eli Lilly & Co and Amylin Pharmaceuticals Inc , that patients need to inject only once a week, failed to match a rival treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback